These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36121156)

  • 1. Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension.
    Ornstová E; Tužil J; Chadimová K; Mlčoch T; Doležal T
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1269-1275. PubMed ID: 36121156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.
    Jain S; Khera R; Girotra S; Badesch D; Wang Z; Murad MH; Blevins A; Schmidt GA; Singh S; Gerke AK
    Chest; 2017 Jan; 151(1):90-105. PubMed ID: 27615023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
    Papademetriou E; Liu X; Beaudet A; Tsang Y; Potluri R; Panjabi S
    J Med Econ; 2023; 26(1):644-655. PubMed ID: 37086091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of riociguat in combination therapies for pulmonary arterial hypertension.
    Rahaghi FF; Trivieri MG; Sahay S
    Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
    Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
    Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    Baker WL; Darsaklis K; Singhvi A; Salerno EL
    Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
    Kenny M; Clarke MM; Pogue KT
    J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
    Jiménez A; Ais A; Beaudet A; Gil A
    Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
    Tsang Y; Stokes M; Kim YJ; Tilney R; Panjabi S
    Clin Respir J; 2023 Dec; 17(12):1209-1222. PubMed ID: 37804160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riociguat: Clinical research and evolving role in therapy.
    Klinger JR; Chakinala MM; Langleben D; Rosenkranz S; Sitbon O
    Br J Clin Pharmacol; 2021 Jul; 87(7):2645-2662. PubMed ID: 33242341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.
    Wang L; Zhu L; Wu Y; Li Q; Liu H
    Ann Palliat Med; 2021 Oct; 10(10):11117-11128. PubMed ID: 34763472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
    McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
    BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Verlinden NJ; Walter C; Raina A; Benza RL
    J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial.
    Weatherald J; Thakrar MV; Varughese RA; Kularatne M; Liu J; Harper L; Kiamanesh O; Fine N; Orlikow E; Nwaroh C; Thornton C; Swiston J; Kolkman L; Brunner NW; Helmersen D; Hirani N
    J Heart Lung Transplant; 2022 May; 41(5):563-567. PubMed ID: 35090807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.